News

FDA’s job cuts paint mixed picture for drugmaker’s R&D plans
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
Japan's Takeda to launch dengue vaccine in India with Biological E next year
Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...
Science-Based Medicine5hOpinion
Hello measles, my old friend: The return of previously vanquished vaccine-preventable diseases
A study published last week suggests that, if vaccine uptake continues to decline, measles will soon be endemic again in the ...
Stocktwits on MSN10h
Novavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval Hopes
Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...
STAT13h
U.S. health officials inject new uncertainty into approval process for Covid boosters
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Devdiscourse16h
Global Health Dynamics: From Ebola to COVID-19 Developments
A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...
WISN 12 News23h
FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval
The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...